This site is intended only for healthcare professionals resident in the Republic of Ireland
A challenge when treating older patients is the lack of evidence to inform delivery of cancer care due to their under-representation in clinical trials. RWE may provide valuable information to supplement available data on efficacy and safety of treatment in this heterogeneous patient group.¹
In real-world studies, older patients with HR+/HER2- mBC derived clinical benefit from IBRANCE combined with ET treatment compared with ET alone.2-4
When analyzed by age group, median rwPFS and median OS remained longer in patients who received IBRANCE in combination with letrozole versus letrozole alone in both the 65–74 and the ≥75-years-old age groups.²
In women with resistant and/or pre-treated mBC, global QoL was maintained at 6 months.5
Following 6 months of IBRANCE treatment, a clinically meaningful reduction in pain scores was observed (≥10 points). No clinically meaningful changes occurred in other domains and scales.5
The toxicity profile for older patients treated with IBRANCE was consistent with that seen in clinical trials.6,7 No new safety signals were detected.6
Legal Category: S1A
Further information is available upon request
Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
Adverse events should also be reported to Pfizer Medical Information on 1800 633 363
Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.
This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie
This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.
Copyright © 2023 Pfizer Limited. All rights reserved.
The information contained on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland.
I confirm that I am a healthcare professional resident in the Republic of Ireland.*
If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.
PP-UNP-IRL-0176. January 2023